First Tracks Biotherapeutics reported a net loss of $31.4 million for the third quarter ended September 30, 2026, as a reduction in legacy program spending offset clinical progression costs. The results were highlighted by statistically significant Phase 1b data for lead candidate ANB033 in celiac disease and a substantial capital injection that extended the company's financial runway into 2027.
Key Highlights
- Clinical trials for ANB033 in celiac disease met primary goals, demonstrating a statistically significant protective effect on intestinal damage with a +0.49 placebo-adjusted delta (p=0.009).
- Financial liquidity reached a pro forma balance of $343 million following a $200 million private placement completed in October 2026.
- Research and development expenses declined 28% year-over-year to $23.8 million due to decreased development costs for the rosnilimab and ANB032 programs.